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Vaccine Reports
Background: Vaccine-induced immunity against pneumococcal infection 
relies on the generation of high concentrations of antibody and B cell mem-
ory. Both the 10- and the 13-valent pneumococcal conjugate vaccines (PCV-
10 and PCV-13) effectively reduce disease caused by vaccine serotypes. It is 
unknown whether the generation of B cell memory requires several doses of 
the same vaccine or whether different PCVs are interchangeable.
Methods: Children in the United Kingdom (n=178) who had previously 
received PCV-13 at 2 and 4 months were randomized 1:1 to receive a PCV-
13 or PCV-10 booster at age 12 months. Peripheral blood memory B cells 
(B
MEM
) were quantified before and at 1 and 12 months after vaccination 
using a cultured enzyme-linked immunospot assay for pneumococcal sero-
types 1, 3, 4, 9V, 14, 19A, and diphtheria and tetanus toxoid. Correlations 
between B
MEM
 frequencies and simultaneously measured antibody (IgG and 
opsonophagocytic assay) was also assessed.
Results: A significant rise in postbooster B
MEM
 frequency was seen for 5 out 
of 6 serotypes in the PCV-13 group and none in the PCV-10 group. In the 
PCV-13 group, there was a particularly large increase in serotype 3–specific 
B
MEM
 associated with only a small increase in antibody. Postbooster B
MEM
 
responses correlated positively with antibody, but correlations between 
prebooster B
MEM
 and subsequent B
MEM
 and antibody responses were incon-
sistent.
Conclusions: After priming with PCV-13 in early infancy, a booster dose of 
PCV-10 does not induce detectable peripheral blood B
MEM
 responses but a 
PCV-13 booster does induce robust responses. Booster responses to PCVs 
may be dependent on homologous carrier protein priming.
Key Words: vaccination, interchangeability, pneumococcal conjugate vac-
cine, memory B cells
(Pediatr Infect Dis J 2017;36:e130–e135)
INTRODUCTION
Vaccination against Streptococcus pneumoniae with cur-
rently used 10- and 13-valent pneumococcal conjugate vaccines 
(PCV-10 and PCV-13) has been shown to dramatically reduce vac-
cine-type invasive pneumococcal disease when included in child-
hood immunization schedules.1–5 Both vaccines are immunogenic 
and have been shown to induce immune memory.6,7
There is limited information on the interchangeability of 
PCVs; however; there are potential reasons why it may be advanta-
geous to include PCV-10 in the infant vaccination schedule. Non-
typeable Haemophilus influenzae (NTHi) protein D is not included 
in any concurrent or previously administered vaccine. Its use may, 
therefore, reduce the risk of immune interference and theoretically 
increase the immune response to the polysaccharides. Immune 
interference can occur if the same carrier protein is used in con-
current or sequential vaccinations and can suppress the immune 
response to the desired antigen.8 In addition, use of NTHi protein D 
as a carrier protein may confer additional protection against NTHi 
infection, a common cause of otitis media in children,9 although 
effectiveness of PCV-10 against NTHi carriage or disease has not 
been demonstrated in previous vaccine trials.10–12
Ideally, a vaccine should provide long-lasting protection 
in the form of antibodies, but should also induce immunological 
memory through the formation of memory B cells (B
MEM
). A num-
ber of investigators have studied this outcome by measuring B
MEM
 
frequency in peripheral blood after vaccination.13–16 The majority 
of B
MEM
 is thought to reside in lymphoid tissue, but small numbers 
of circulating B
MEM
 can be detected in peripheral blood even years 
after vaccination. The frequency of these cells in peripheral blood 
rises shortly after vaccination, particularly after booster doses.17 
Re-encounter with antigen triggers the proliferation of B
MEM
 and 
their differentiation into antibody-secreting plasma cells, giv-
ing rise to a rapid and effective secondary immune response. The 
presence of B
MEM
 may also contribute to the maintenance of circu-
lating antibody by intermittent or continuous differentiation into 
antibody-secreting plasma cells in response to antigen-dependent 
or independent stimulation.18
This study evaluated the potential for the use of PCV-10 as 
a booster after priming with PCV-13 in infancy by assessing non-
inferiority of the proportions of participants with postbooster IgG 
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≥ 0.35 μg/mL for PCV-10 serotypes. The results of antibody meas-
urements in this cohort of children have already been published and 
showed that in PCV-13-primed infants, a booster dose of PCV-10 
induces a strong antibody response, which is generally less pro-
nounced than the response after a PCV-13 booster.19 In the analysis 
presented here, we investigated the frequencies of peripheral blood 
B
MEM
 before and at 1 and 12 months after a 12-month booster dose 
of PCV-10 or PCV-13. Using a cultured enzyme-linked immuno-
spot (ELISpot) assay, we studied the B
MEM
 response to 2 different 
pneumococcal vaccines, of which only one had previously been 
given to study participants. By comparing the booster response to 
the 2 vaccines, which differ in the concentrations of pneumococcal 
polysaccharides, the method of conjugation and the type and con-
centrations of the carrier proteins, we had the unique opportunity to 
study the effects of a mixed vaccination schedule on B cell biology.
MATERIALS AND METHODS
Subjects and Vaccines
Healthy children who had been vaccinated with the PCV-13 
at 2 and 4 months of age were recruited as previously described19 
(Fig., Supplemental Digital Content 1, http://links.lww.com/
INF/C656). Ethical approval was obtained from the Oxfordshire 
Research Ethics Committee (reference number 11/SC/0473), and 
the study was registered on Clinicaltrials.gov (registration number 
NCT01443416). After enrolment into the study, these children were 
randomized to receive either PCV-10 [Synflorix, GSK Biologicals; 
containing capsular polysaccharides of serotypes 1, 4, 5, 6B, 7F, 
9V, 14, 18C, 19F and 23F, conjugated to NTHi protein D, tetanus 
toxoid (18C) or diphtheria toxoid (19F), respectively] or PCV-13 
[Prevenar 13, Pfizer; containing serotypes 3, 6A and 19A in addi-
tion to PCV-10 serotypes, conjugated to diphtheria toxin mutant or 
cross reactive material (CRM
197
)]. Blood samples were taken on 3 
visits: at day 0 immediately before vaccination (12 months of age) 
and at 1 and 12 months after vaccination (13 and 24 months of age).
Peripheral Blood Mononuclear Cell isolation and 
ELISpot
The cultured ELISpot assay for the detection of antigen-spe-
cific B
MEM
 was performed as previously described.20 First, periph-
eral blood mononuclear cells were isolated from whole blood by 
density gradient centrifugation with lymphoprep (Axis-Shield). 
Cells were then cultured for 6 days at 37°C in 5% carbon diox-
ide and 95% humidity with an antigen stimulation mix containing 
Staphylococcus aureus Cowan strain (Calbiochem-Novabiochem) 
at a 1:5000 dilution, poke weed mitogen (Sigma-Aldrich) at a 
final concentration of 83 ng/mL and CpG oligonucleotide (Invi-
voGEN) at a final concentration of 1.7 μg/mL. After harvesting, 
cells were washed and seeded at 2 × 105 viable cells per well onto 
a 96-well plate with PVDF membranes (Millipore). Membranes 
were precoated with either pneumococcal polysaccharides (1, 3, 
4, 9V, 14 and 19A; LCG Promochem) conjugated to methylated 
human serum albumin (NIBSC UK), diphtheria toxoid (10 μg/mL, 
also used to represent the CRM
197
 carrier protein; Statens Serum 
Institut), or tetanus toxoid (5 μg/mL, Statens Serum Institut). Pneu-
mococcal serotypes were chosen to reflect serotypes contained in 
both PCV-10 and PCV-13 (serotypes 1, 4, 9V and 14) or unique 
to PCV-13 (serotypes 3, 19A). Plates included phosphate-buffered 
saline wells and polyvalent goat anti-human immunoglobulin (10 
μg/mL) wells as negative and positive controls, respectively. After 
overnight incubation, plates were washed, and bound IgG antibody 
was detected using a goat anti-human IgG alkaline phosphatase 
conjugate (Calbiochem) and alkaline phosphatase substrate kit 
(Bio-Rad). Plates were dried overnight before being read using an 
automated ELISpot reader (AID ELR03, AID Diagnostika). All 
plate readings were manually checked to exclude artifacts.
Data Analysis
The average number of spots per well was used to calculate 
the number of antibody-secreting cells per million peripheral blood 
mononuclear cells. If any spots were observed in the control phos-
phate-buffered saline wells, the average count across these control 
wells was subtracted from the average count from each type of 
antigen-coated well. Wells coated with total immunoglobulin were 
used as positive controls. Results of zero were assigned the value 
of 0.625 per million peripheral blood mononuclear cells (half of 
the lower limit of detection). Geometric mean frequencies (GMF) 
and corresponding 95% confidence intervals were calculated for 
each group and study time point. Differences between groups and 
time points were investigated using 2-sample t tests of logarithmi-
cally transformed B
MEM
 frequencies and Satterthwaite’s correction 
for unequal variances. Correlations between responses at different 
time points were assessed using the Pearson correlation coefficient.
RESULTS
Samples
Out of a total of 434 blood samples across both groups 
and the 3 study visits from the original serological analysis,19 377 
(87%) samples had cells available for B
MEM
 and antibody analysis. 
The breakdown of samples by visit and vaccine group is shown in 
Table 1.
Antigen-specific BMEM GMF by Antigen and  
Vaccine Group
At 12 months of age, B
MEM
 frequencies were low, and no sig-
nificant differences between the groups were seen in B
MEM
 GMF for 
all antigens tested (Figure 1; Table, Supplemental Digital Content 
2, http://links.lww.com/INF/C657). One month after booster vac-
cination at 13 month of age, significantly higher B
MEM
 GMF were 
found for serotypes 1, 4, 9V and 3 in the PCV-13 compared with 
the PCV-10 group, whereas B
MEM
 responses to tetanus toxoid were 
statistically higher in PCV-10 than in PCV-13 recipients (Figure 1; 
Table, Supplemental Digital Content 2, http://links.lww.com/INF/
C657). One year after booster at 24 months of age, no significant 
differences were detected between the groups for any of the anti-
gens tested (Figure 1; Table, Supplemental Digital Content 2, http://
links.lww.com/INF/C657).
Antigen-specific BMEM Frequency Fold Changes
Significant increases between B
MEM
 measured at age 12 and 
13 months were seen for most pneumococcal serotypes in the PCV-
13 group (with the exception of serotype 14, which showed a 1.6-
fold increase with a borderline P value of 0.05) and none in the 
TABLE 1. Number of samples received at each visit for 
each vaccine group that were available for both BMEM and 
antibody analysis
Group
Visit 1  
(12 Months)
Visit 2  
(13 Months)
Visit 3  
(24 Months)
PCV-10 59 (67, 88%) 56 (69, 81%) 66 (75, 88%)
PCV-13 63 (73, 86%) 69 (74, 93%) 64 (76, 84%)
Values in brackets show the number of available serum samples per visit and vac-
cine group, as well as the percentage of samples on which both analyses were done.
BMEM indicates memory B cells; PCV-10, 10-valent pneumococcal conjugate vac-
cines; and PCV-13, 13-valent pneumococcal conjugate vaccines.
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PCV-10 group (Table 2). For antigens representing carrier proteins, 
a significant rise in B
MEM
 frequencies was seen for both diphthe-
ria and tetanus toxoid in the PCV-10 group but only for diphtheria 
toxoid in the PCV-13 group (Table 2). When adjusted for baseline 
B
MEM
 values, age, sex and ethnicity, changes in B
MEM
 frequencies 
between age 12 and 13 months were significantly greater in the 
PCV-13 compared with the PCV-10 group for all pneumococcal 
serotypes and statistically superior in PCV-10 compared with PCV-
13 recipients only for tetanus toxoid (Table 2). Frequencies of B
MEM
 
were not significantly different between age 12 and 24 months for 
most serotypes in both groups. In the PCV-10 group, significantly 
higher B
MEM
 frequencies were seen for serotypes 14 (GMF of 3.83 
versus 1.91) and 19A (4.76 versus 2.66) at 24 months compared 
with 12 months of age, whereas in the PCV-13 group, a signifi-
cant fold increase was only seen for serotype 3 (2.88 versus 1.61; 
Table, Supplemental Digital Content 3, http://links.lww.com/INF/
C658). However, when comparing these fold changes from age 12 
to 24 months between the vaccine groups, no differences were seen 
when adjusted for baseline values, age, sex and ethnicity (data not 
shown).
Correlation Between Serotype-specific BMEM and 
Antibody Responses
Pearson correlation was used to investigate correlations 
between log-transformed B
MEM
 frequencies at different time points 
and between B
MEM
 and antibody responses (both IgG concentra-
tion and opsonophagocytic assay titers). All correlations and their 
statistical significance are shown in Figure 2. The most striking 
correlations were seen between B
MEM
 and antibody, both at age 13 
months. Antibody and B
MEM
 were correlated at 12 months and at 24 
months of age for some serotypes; however, this relationship was 
less consistent than that seen at age 13 months. B
MEM
 at 12 and 13 
months of age were also predictive of later antibody responses for 
some serotypes in each group, but again this relationship was not 
consistent across serotypes.
A significant increase in B
MEM
 frequencies from 12 to 13 
months of age against the majority of the tested serotypes was only 
observed for the PCV-13 group, but the extent of the response was 
serotype dependent (Table 2). In PCV-13 recipients, the immune 
response against serotype 3 was associated with a strong increase 
in peripheral B
MEM
 (Figure 2) and associated with a weak antibody 
FIGURE 1. Geometric mean 
frequencies [GMF; along 
with 95% confidence interval 
(CI)] of memory B cells (BMEM) 
specific for pneumococcal 
serotypes, as well as 
diphtheria and tetanus toxoid. 
Groups were compared by 
independent samples t tests 
using log10-transformed data 
with Satterthwaite’s correction 
for unequal variances. Stars 
indicate the associated P 
value (***<0.001; **<0.01; 
*<0.05). 1/4/9V/14/3/19A 
indicates pneumococcal 
serotypes 1/4/9V/14/3/19A; 
Dip, diphtheria toxoid; PBMC, 
peripheral blood mononuclear 
cells; PCV-10, 10-valent 
pneumococcal conjugate 
vaccines; PCV-13, 13-valent 
pneumococcal conjugate 
vaccines; and Tet, tetanus 
toxoid.
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responses compared with other serotypes.19 In contrast, antibody 
responses against serotype 14 were strong,19 whereas it was asso-
ciated with only a small increase in postbooster B
MEM
 frequency 
(Figure 2).
DISCUSSION
This study provides an assessment of the B
MEM
 responses 
after booster vaccination with either PCV-13 or PCV-10 in children 
previously primed with 2 doses of PCV-13. Our results show 
that PCV-13-primed children do not generate peripheral B
MEM
 in 
response to a PCV-10 booster. This is a surprising finding because 
4 of the 6 serotypes that were evaluated are contained in both vac-
cines. However, the vaccines differ in the concentrations of pneu-
mococcal polysaccharides, the method of conjugation and the type 
and concentrations of the carrier proteins, which may result in 
diverging presentation and processing of antigens.
TABLE 2. Antigen-specific BMEM frequency geometric mean fold change from 12 to 13 months by vaccine 
group
Serotype
PCV-10 PCV-13 Adjusted Treatment (Group) Effect*
N
Geometric 
Mean Fold 
Rise† 95% CI P Value N
Geometric 
Mean Fold 
Rise† 95% CI P Value
PCV-10/ 
PCV-13 95% CI P Value
1 39 1.160 0.714–1.886 0.544 54 2.436 1.530–3.877 <0.001 0.469 0.284–0.773 0.003
4 39 0.929 0.563–1.532 0.770 54 2.917 1.855–4.588 <0.001 0.340 0.210–0.550 <0.001
9V 38 0.880 0.504–1.537 0.650 54 3.091 1.872–5.105 <0.001 0.295 0.172–0.506 <0.001
14 38 1.025 0.613–1.713 0.925 54 1.556 1.000–2.420 0.050 0.582 0.352–0.964 0.036
3‡ 39 0.809 0.549–1.191 0.278 54 12.90 8.587–19.37 <0.001 0.057 0.037–0.086 <0.001
19A‡ 38 1.775 0.996–3.161 0.051 53 3.238 1.951–5.373 <0.001 0.429 0.240–0.766 0.005
Dip§ 33 2.157 1.231–3.780 0.008 51 2.660 1.568–4.510 <0.001 0.865 0.525–1.426 0.566
Tet¶ 35 2.249 1.089–4.643 0.029 51 1.084 0.604–1.944 0.785 2.188 1.229–3.894 0.008
N indicates number of paired samples.
*Ratio of geometric mean fold rises from 12 to 13 months (PCV-10/PCV-13), adjusted for 12 month values, age, sex and ethnicity.
†Geometric mean change from 12 months to 13 months.
‡Serotypes contained in PCV-13 only.
§Represents carrier protein CRM197 (PCV-13) or diphtheria toxoid (PCV-10).
¶Represents carrier protein tetanus toxoid (contained in PCV-10 only).
1/4/9V/14/3/19A indicates pneumococcal serotypes 1/4/9V/14/3/19A; BMEM, memory B cells; CI, confidence interval; Dip, diphtheria toxoid; PCV-10, 10-valent 
pneumococcal conjugate vaccines; PCV-13, 13-valent pneumococcal conjugate vaccines; and Tet, tetanus toxoid.
FIGURE 2. Correlation between memory B cells (BMEM) frequency at 12, 13 and 24 months of age and BMEM frequency at 
other time points, IgG and OPA. NS indicates not significant; and OPA, opsonophagocytic assay.
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One recent study assessed the short-term (7–9 days after 
booster) immunogenicity and the plasma and B
MEM
 response around 
a booster dose given at 11 months of age after a vaccination series 
with either PCV-10 or PCV-13.21,22 This study showed that the pneu-
mococcal serotype-specific frequencies of peripheral blood B
MEM
 
measured before and shortly after a PCV booster were significantly 
higher in PCV-13 compared with those in PCV-10 recipients for 3 out 
of 4 serotypes common to both vaccines.21 No such differences were 
seen for serotype-specific plasma cell responses,21 but the study also 
showed statistically superior postbooster IgG responses in the PCV-13 
compared with the PCV-10 group to the majority of serotypes com-
mon to both vaccines.22 After 4 doses of PCV-10, a significant B
MEM
 
booster response was observed21; however, even in that study, PCV-13 
appeared to be a more potent inductor of B
MEM
 than PCV-10. Inter-
changeability of PCVs was not assessed in that study because children 
received the same booster vaccine as they had received in infancy.
In the present clinical trial, in the PCV-10 group, no change in 
serotype-specific B
MEM
 frequencies was seen between before booster 
and 1 month later booster vaccination, whereas a significant increase 
in B
MEM
 specific for diphtheria and tetanus toxoid was noted between 
these 2 study time points. Children who were allocated to the PCV-10 
group had previously received 2 doses of PCV-13 and were, there-
fore, already primed with all pneumococcal serotypes contained in 
PCV-10. However, their immune system had not been exposed to the 
same conjugates and the carrier protein D derived from NTHi in the 
form of a vaccine, although some may have encountered it through 
carriage or disease. Priming and boosting with different carrier pro-
teins has previously been investigated in children vaccinated against 
meningitis C.23 Children primed with a dose of tetanus toxoid–conju-
gated polysaccharide (MenC-TT) at 3 months generated better B
MEM
 
responses to a MenC-TT booster at 12 months than those primed 
with either 1 or 2 doses of CRM-conjugated polysaccharide (MenC-
CRM). In the present study, B
MEM
 booster responses to serotypes 18C 
and 19F, which are conjugated to tetanus and diphtheria toxoid, respec-
tively, were not assessed. Investigating 18C and 19F B
MEM
 responses 
to a booster dose of PCV-10 in PCV-13-primed children may have 
provided further insight into whether exposure to the carrier protein 
through routine vaccination (as these children have already received 
several doses of diphtheria and tetanus toxoid–containing vaccines) 
is enough to generate pneumococcal B cell memory in these children 
or whether the carrier protein has to be conjugated to pneumococ-
cal polysaccharides to achieve effective priming. In the meningitis C 
study, children primed with MenC-CRM generated inferior booster 
B cell responses to a MenC-TT booster, despite previous exposure 
to tetanus toxoid in other routine vaccinations,23 suggesting that in 
children of this age group, priming with a similar carrier protein is 
essential for B
MEM
 generation. Overall, the findings of the present 
study suggest that in children previously primed with PCV-13, the 
protein D–conjugated polysaccharides in a booster dose of PCV-10 
appear to evoke a primary rather a secondary immune response. This 
may involve, in the short term, processing of antigens similar to plain 
polysaccharides (which do not generate B
MEM
 responses) rather than 
recognition as T-dependent antigens. Future studies are needed to 
explore in detail the observed lack of B cell responses after PCV-10 
vaccination, especially by investigating responses in children primed 
with PCV-10 and boosted with PCV-13.
In the group of children who were primed and boosted with 
PCV-13, the B
MEM
 peak at age 13 months was followed by a return 
to almost baseline by age 24 months for most serotypes, by which 
time most cells have probably transited to lymph nodes. In PCV-
10 recipients, previously receiving PCV-13 primary vaccination, an 
increase in B
MEM
 frequencies was seen between 12 and 24 months 
of age for all serotypes tested, which was significant for serotype 14 
and serotype 19A (Table, Supplemental Digital Content 3, http://
links.lww.com/INF/C658). These findings suggest that there was 
a slower generation of B
MEM
 in response to PCV-10 vaccination 
or ongoing generation through natural exposure via carriage,24,25 
resulting in some increase in B
MEM
 frequencies in the peripheral 
blood 1 year after the booster vaccination.
It is possible that because of differences between polysac-
charides in the vaccine and those bound to the ELISpot plates, the 
assay used in this study was less able to detect B
MEM
 induced by the 
PCV-10 vaccine, despite their presence in peripheral blood. How-
ever, the fact that a late rise in B
MEM
 was detected in the PCV-10 
group at age 24 months makes this explanation less likely.
In the PCV-13 group, the most marked B
MEM
 response was 
seen for serotype 3. However, the immune response to serotype 3 
polysaccharide has previously been shown to be atypical, and anti-
body responses to a booster appear to be particularly impaired.26 
Compared with other serotypes, immunogenicity for serotype 3 
is attenuated and a serotype 3–containing vaccine has previously 
failed to show protective efficacy against serotype 3 otitis media,9 
although postimplementation surveillance suggests that immuni-
zation with PCV-13 does have some efficacy against serotype 3.27 
Despite diminished antibody production, the B
MEM
 response to 
serotype 3 polysaccharide has previously been shown in adults to 
resemble that of other serotypes.28 In the present analysis, serotype 
3 showed both the greatest increase in B
MEM
 frequency and the low-
est antibody response of all PCV-13 serotypes (Figure 1),19 sug-
gesting that one reason for impaired serotype 3–specific antibody 
concentrations after a booster might be that the immune response is 
driven towards the generation of B
MEM
 rather than antibody-secret-
ing cells but still provides some protection.
A question addressed by a number of studies has been 
whether baseline B
MEM
 positively correlate with later antibody 
responses.17 A correlation between B
MEM
 frequency after priming 
and antibody persistence at 1 year was found in children receiving 
the meningococcal serotype C conjugate vaccine,16 and for some 
meningococcal serogroups in children receiving the MenACWY 
vaccine29; however, no relationship between B
MEM
 and antibody 
was found in older children receiving a booster dose of the Hib-
MenC conjugate vaccine.30 Here we show that B
MEM
 and antibody 
responses 1 month after booster correlate well for most serotypes, 
particularly in PCV-13 recipients; however, baseline B
MEM
 are not 
a consistent predictor of postvaccination B
MEM
 and IgG responses. 
This may reflect the unmeasured contribution of other antibody-
producing cell types, such as long-lived plasma cells.
CONCLUSION
Here we present the first study assessing the B
MEM
 response to 
a mixed PCV schedule. We were unable to detect serotype-specific 
B
MEM
 after a booster dose of PCV-10 given to children who had been 
primed with PCV-13. In contrast, a strong serotype-specific B
MEM
 
response was generated in children primed with PCV-13 after receipt 
of a PCV-13 booster. These findings suggest that immunizing with a 
PCV containing polysaccharides conjugated to a novel carrier pro-
tein is not sufficient to generate a rapid and strong B
MEM
 response, at 
least when primary vaccination with PCV-13 is followed by a booster 
dose of PCV-10. Although the clinical implications of these results 
are unknown, they still indicate that a vaccination series only using 
PCV-13 is advantageous over a mixed PCV schedule consisting of a 
priming series with PCV-13 and boosting with PCV-10.
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